Variable vs. Fixed Dosing of Monoclonal Antibodies in Oncology

Abstract

Oncological patients need the proper doses of medications to facilitate their recovery. The two basic approaches used in dosing Monoclonal Antibodies (mAbs) are fixed-dose combination and variable dosing. In Fixed-Dose Combination Drugs (FDCs), two or more active components are combined in a single formulation at a predetermined dose. Variable dosage, which has long been the industry standard, is the polar opposite of this approach. The body changes over time; the Body Surface Area (BSA) in square meters is often used as a Measure (m2). This study uses a systematic review. Most mAbs used in oncology are predominantly given as cytotoxic anticancer drugs using body-size-based (variable) regimens. Despite the benefits of fixed-dose, variable dosing has become the industry standard, despite being criticized for ineffectiveness. While variable dosing has some advantages, the prevalent view is that continuous dosing has significant advantages based on the balance of probabilities. After assessing each alternative, including its benefits and drawbacks, history of use, and suitability in the current context, fixed dosing emerges as a viable option.

Cancer Patients' Quality of Life

“…In cancer research this point has turned out to be very relevant, because the QL is mostly judged by those treating or nursing the patient. If QL has been measured in cancer trials the Karnofsky and the Zubrod indexes (42,43] are the measures most commonly used 17 J. These scales are filled in by physicians and therefore represent their evaluation of the situation.…”

Cancer Targeted Therapy: The Next Generation of Treatment

“…Novel approaches are being developed to better treat cancer patients and complement current traditional therapies. Two types that are currently being developed are small molecule inhibitors and monoclonal antibodies [33][34][35]. Small molecule inhibitors focus on inhibiting kinases and preventing activation of pathways that are dysregulated during cancer.…”

“…4). Moreover, Herceptin is able to increase the rate of endocytosis of HER2 resulting in a decrease in the amount of HER2 present on the plasma membrane [35]. Furthermore, Herceptin is able to increase the ability of the immune system to detect the cancerous cells by binding to cancer cells overexpressing HER2.…”

Measurement of involvement in human-robot interaction produced by eye contact

“…Here, we would like to specifically focus on eye tracking as an implicit measure of engagement [6][7]12], as eye movements are particularly informative with respect to attentional processes [36]. In the context of social interaction, eye movements are not only informative with respect to the individual's attentional focus, but they are also signaling to others where attention is oriented.…”